Australian biotech market watch 19/03/10
Friday, 19 March, 2010
At the end of a buoyant week for the stock market, the All Ordinaries is flat as of midday today, up a marginal 6.5 points to 4,884.20.
After Cochlear (ASX:COH) announced a change of chairman as Tommie Bergman indicated he was to step down, stocks in the company have seen a bump, up 3.86% since the announcement to $69.30 today.
Two of the other Big Three have remained fairly steady, with CSL (ASX:CSL) hovering around the $36 mark and ResMed loitering around $6.73.
Xenotransplantation specialists, Living Cell Technology (ASX:LCT), saw a steep rise early in the week, but much of the gains have been lost Thursday and today, with it dropping 2c to 21c, although that's still above the sub-20c mark it was trading at last week.
Mesoblast (ASX:MSB) is fairly steady today, up 1c to $2.06, but saw a tidy 5% lift in yesterday's trading.
Heart muscle regeneration genes mapped
Researchers have uncovered insights into how stem cells develop and mature into heart muscle...
The cause of 2022's mpox outbreak revealed
Researchers have discovered that the strain of mpox behind the 2022 outbreak was a weakened form...
New gene therapy treats liver disorder in growing children
Researchers have developed a genome-editing approach that repairs a faulty gene directly at its...
